9. Jul 2026
Description
(AWP Alliance News) - Roche on July 9, 2026 received a CE Mark for its Elecsys IGRA TB blood test, adding a new automated option for latent tuberculosis screening on its widely installed cobas immunoassay systems. The move strengthens Roche's competitive position in infectious disease diagnostics by leveraging its existing instrument base to scale testing volumes with less manual labor.
Roche expects the launch to support faster lab turnaround, which could help win share as health systems expand screening to curb transmission and meet WHO elimination targets. Clinical data showed 91.12% positive percent agreement and 94.57% negative percent agreement versus standard-of-care methods, supporting adoption in routine settings.
https://www.publicnow.com/view/AF15C4075498CF37B229CFD9AF9B9DB4D2DF0D24…
Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.
